Pricing Log in Create free account

Caris Life Sciences,�Inc. (CAI) vs ImmunityBio, Inc. (IBRX)

Caris Life Sciences,�Inc. and ImmunityBio, Inc. are both Biotechnology companies. ImmunityBio, Inc. is the larger, with a market value of $8.5B against $7.4B — 1.2× the size. ImmunityBio, Inc. has negative trailing earnings, so its P/E is not meaningful; Caris Life Sciences,�Inc. trades at 77.7×. ImmunityBio, Inc. grew revenue faster over the last twelve months: 192.9% against 68.8%. Caris Life Sciences,�Inc. has the higher net margin (9.16% vs −598.6%) and the higher return on invested capital (22.2% vs 0.00%). Across the 16 metrics below, Caris Life Sciences,�Inc. leads on 12 and ImmunityBio, Inc. on 4.

Valuation

Metric CAI IBRX Biotechnology median
P/E 77.71 n/m 10.26
P/S 7.15 51.05 9.18
P/B 12.66 n/m 2.05
Price to free cash flow 190.71 n/m 24.81
EV/EBITDA 39.40 n/m 0.65
EV/Sales 6.77 56.47 8.98
Earnings yield 1.29% (12.03%) (34.89%)
Free cash flow yield 0.52% (3.40%) (24.52%)

Profitability

Metric CAI IBRX Biotechnology median
Gross margin 0.00% 99.34% 65.16%
Operating margin 13.35% (151.88%) 0.00%
Net margin 9.16% (598.56%) 0.00%
Free cash flow margin 8.00% (173.76%) 0.00%
Return on equity 0.00% 122.85% (50.12%)
Return on assets 8.58% (192.58%) (45.60%)
Return on invested capital 22.24% 0.00% 0.00%

Growth

Metric CAI IBRX Biotechnology median
Revenue growth (TTM) 68.84% 192.92% 6.26%
EPS growth (last fiscal year) 69.79% 38.71% 29.88%
Revenue growth, 5-year CAGR — 184.76% 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric CAI IBRX Biotechnology median
Debt to equity 0.00 (0.74) 0.00
Current ratio 6.71 5.72 4.89
Net debt to EBITDA (5.23) (0.97) 1.01

Dividend

Metric CAI IBRX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CAI IBRX Biotechnology median
Market cap 7.36b 8.49b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack